DARE - Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms

• Daré Bioscience ( NASDAQ: DARE ) is trading 6.5% higher after the company announced positive data from its Phase 1/2 clinical trial of investigational intravaginal ring, DARE-HRT1, to treat the vasomotor symptoms and genitourinary syndrome associated with menopause.
• The drug is designed to deliver bio-identical 17?-estradiol and bio-identical progesterone continuously over a 28-day period as part of a hormone therapy regimen.
• The topline data from the study showed improvement in both vasomotor symptoms as well as vaginal symptoms of menopause.
• The primary objective or the main goal of the study was to demonstrate the safety, tolerability, and pharmacokinetics (PK) of two different dose combinations over 12 weeks of use.
• The company said the levels of estradiol released from both the lower and higher dose formulation of DARE-HRT1 evaluated in the study achieved statistically significant improvement.
• Menopausal symptoms, including hot flashes and night sweats, were reduced compared with baseline in both DARE-HRT1 dose groups.
• The topline PK data from the study will be available later in Q4.

For further details see: